AllianceBernstein’s aTyr Pharma ATYR Stock Holding History

AllianceBernstein’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64,480	Closed	-$50.5K	–	3447
2026 Q1	$50.5K	Hold	64,480	–	–	﹤0.01%	3199
2025 Q4	$50.5K	Hold	64,480	–	–	﹤0.01%	3206
2025 Q3	$46.5K	Hold	64,480	–	–	﹤0.01%	3219
2025 Q2	$327K	Buy	64,480 +12,563	+24%	+$49.4K	﹤0.01%	2874
2025 Q1	$157K	Buy	+51,917	New	+$189K	﹤0.01%	2981

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AllianceBernstein's ATYR Position: Q2 2026 in Review

AllianceBernstein sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 64,480 shares — an estimated $50.5K sold.

AllianceBernstein first reported a position in ATYR in Q1 2025 and held it in 5 quarters. The position peaked at $327K in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

AllianceBernstein reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
AllianceBernstein sold 64,480 aTyr Pharma shares in Q2 2026, an estimated $50.5K.
AllianceBernstein first reported a position in aTyr Pharma in Q1 2025 and held it in 5 quarters.
AllianceBernstein's aTyr Pharma position peaked at $327K in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.